文献速递冠心病血脂与心血管预防

IMPROVE-IT 中依折麦布治疗的生物标志物与心血管结局

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究在 IMPROVE-IT 试验的 7,195 例 ACS 后稳定患者中,检测高敏肌钙蛋白 T、NT-proBNP、GDF-15 和高敏 C 反应蛋白,采用多标志物策略评估依折麦布联合他汀的获益。结果显示标志物水平升高与心血管事件风险增加独立相关,且高风险患者(≥3 个标志物阳性)绝对风险降低更明显。

要点

  • ACS 后患者中,四种心血管生物标志物升高均独立关联 CV 死亡/心梗/卒中及 CV 死亡/心衰风险增加。
  • ≥3 个标志物阳性的高风险患者,依折麦布联合他汀的绝对风险差为 -7.3%(95%CI -13.8% 至 -0.8%,P=0.02)。
  • 0 个标志物阳性的低风险患者未观察到依折麦布联合他汀的获益。

核心结论

  • 基于生物标志物的策略可识别 ACS 后患者的风险梯度,高风险患者从依折麦布联合他汀治疗中绝对获益更大。

研究设计与样本

  • IMPROVE-IT 随机双盲试验的预先指定嵌套分析,比较依折麦布/辛伐他汀与安慰剂/辛伐他汀。
  • 在 7,195 例 ACS 后稳定(随机化后 1 个月)患者中检测高敏肌钙蛋白 T、NT-proBNP、GDF-15 和高敏 C 反应蛋白。

主要发现

  • 各生物标志物水平升高均独立关联 CV 死亡/心梗/卒中和 CV 死亡/心衰风险增加(趋势 P<0.001)。
  • 高风险患者(≥3 个标志物阳性,n=1,437)绝对风险差 -7.3%(95%CI -13.8% 至 -0.8%,P=0.02)。
  • 中风险患者(1-2 个标志物阳性,n=3,842)绝对风险差 -4.4%(95%CI -9.7% 至 0.8%)。
  • 高风险和中风险患者 7 年需治疗人数分别为 14 和 23。
  • 低风险患者(0 个标志物阳性,n=1,916)未观察到依折麦布联合他汀的获益。

临床怎么用

  • 对 ACS 后患者可考虑检测高敏肌钙蛋白 T、NT-proBNP、GDF-15 和高敏 C 反应蛋白以进行风险分层。
  • 标志物阳性个数较多的患者可能从依折麦布联合他汀治疗中获得更大的绝对获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Addition of ezetimibe to statin therapy reduces the risk of recurrent cardiovascular (CV) events in patients with prior acute coronary syndrome (ACS). The role of biomarkers in identifying subsets of patients who may derive greater clinical benefit with ezetimibe is unknown. OBJECTIVES: This study sought to evaluate the role of established CV biomarkers in assessing likely benefit with ezetimibe added to statin therapy in post-ACS patients. METHODS: In a pre-specified nested analysis within a randomized, double-blind trial of ezetimibe/simvastatin versus placebo/simvastatin (IMPROVE-IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, growth-differentiation factor-15, and high-sensitivity C-reactive protein was measured in 7,195 patients stabilized (1 month post-randomization) after ACS. A multimarker approach based on biomarker values was used to examine the risk of recurrent CV events and clinical benefit with ezetimibe. RESULTS: Elevated levels of each biomarker were independently associated with higher risks of CV death/myocardial infarction/stroke and CV death/heart failure (ptrend < 0.001 for each). There was a pattern of greater absolute risk reduction in CV death/myocardial infarction/stroke with the addition of ezetimibe to statin therapy in patients at higher risk on the basis of biomarker levels. High-risk patients (≥3 biomarkers "positive"; n = 1,437) had an absolute risk difference of -7.3% (95% confidence interval: -13.8% to -0.8%; p = 0.02) with ezetimibe, and intermediate-risk patients (1 to 2 biomarkers positive; n = 3,842) had an absolute risk difference of -4.4% (95% confidence interval: -9.7% to 0.8%), translating into numbers needed to treat at 7 years of 14 and 23, respectively. Low-risk patients (0 biomarkers positive; n = 1,916) did not appear to benefit from the addition of ezetimibe to statin therapy. CONCLUSIONS: A biomarker-based strategy identifies a gradient of risk among patients post-ACS, offering the potential to identify higher-risk patients with a correspondingly high absolute benefit from the addition of ezetimibe to statin therapy.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Qamar A, Giugliano RP, Bohula EA, et al. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019. PMID: 31439215. doi:10.1016/j.jacc.2019.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。